Cumberland Pharma enters $100M strategic transaction with Apotex, reports Q1 revenue $9.1M

CUMBERLAND PHARMACEUTICALS INC

Entered $100M cash deal to sell FDA-approved brand portfolio to Apotex Inc.; subject to shareholder approval and closing conditions.
Q1 net revenue $9.1M (+5% ex-$3M prior-year milestone); net loss $3.3M; adjusted loss $0.13/share.
FDA granted Fast Track Designation for ifetroban in Duchenne Muscular Dystrophy; Phase II study showed breakthrough results.
Ended quarter with $11M cash, $5.2M drawn on credit facility, total assets $71M, equity $21.6M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CUMBERLAND PHARMACEUTICALS INC reported three months ended March 31, 2026 results: revenue $9.1 million, net income net loss for the first quarter of 2026 was approximately $3.3 million, EPS $0.13 per share.

Period: three months ended March 31, 2026
Revenue: $9.1 million
Net income: net loss for the first quarter of 2026 was approximately $3.3 million
EPS: $0.13 per share
Result: reported results

Exact text from the filing

Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders’ equity. “We

View on SEC.gov

Browse all earnings releases →

CUMBERLAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001087294-26-000046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.